EJNMMI Research

Table 2 Histopathological assessment of mice treated with DOTA_Miltuximab®, 3Mbq [177Lu]Lu-DOTA-Miltuximab® or 10Mbq [177Lu]Lu-DOTA-Miltuximab®

From: Targeted beta therapy of prostate cancer with ¹⁷⁷Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

	DOTA-Miltuximab®							3Mbq [¹⁷⁷Lu]Lu-DOTA-Miltuximab®								10Mbq [¹⁷⁷Lu]Lu-DOTA-Miltuximab®
	Mouse number
Organ	4.1	4.2	4.4	5.1	5.2	5.3	5.4	1.1	1.4	3.3	3.4	6.1	6.2	6.3	6.4	1.2	1.3	1.5	2.1	2.2	2.3	2.4	3.1	3.2
Brain	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Heart
Vasculitis, focal	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Epicardial mineralisation	0	0	0	0	0	0	0	0	2	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0
Lung
Inflammation, granulomatous	0	0	NT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Perivascular lymphocytes	0	0	NT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0
Liver
Neutrophilic infiltrate	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	0	0	0	0
Mononuclear/mixed cell infiltrate	0	1	1	1	1	0	0	3	0	1	1	1	0	0	1	1	1	1	3	2	0	1	0	0
Fatty change	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	1	0	0	1	0
Kidneys
Tubular epithelial basophilia, cortex	1	1	0	1	1	1	1	0	0	0	0	1	0	1	0	1	1	0	0	0	1	1	1	1
Inflammation, interstitial, cortex	1	0	0	1	0	0	0	1	0	0	1	1	0	0	0	1	2	1	0	1	2	1	1	1
Pyelonephritis	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0	0
Spleen	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Small intestine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Testes	0	0	0	0	0	0	1	1	0	0	1	0	1	0	0	0	1	0	0	0	0	0	0	0

NT not tested
0 = no abnormalities, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe

Back to article page